Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01056029 · ClinicalTrials.gov registry record · Phase 1

Dose-Escalation Phase 1 Study of G-202 (Mipsagargin) in Patients With Advanced Solid Tumors

A Phase 1 study of Advanced Solid Tumors, sponsored by GenSpera.

Completed
Registry status
Phase 1
Development phase
30
Enrollment target
3
Study locations

NCT01056029 is a Phase 1 study of Advanced Solid Tumors that has completed, run by GenSpera. The registered enrollment target is 30 participants, below the 198-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (85% lower). The trial reports 3 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01056029, a Phase 1 study of Advanced Solid Tumors, has completed, sponsored by GenSpera.

COMPLETED
Registry status
Phase 1
Development phase
30 participants
Enrollment target
3
Study locations

Study Summary

This is an open-label, single-arm, dose-escalation Phase I study to determine the maximum tolerated dose (MTD) of G-202 (mipsagargin) when administered once daily for 3 consecutive days of a 28-day cycle in patients with advanced solid tumors. G-202 will be administered by intravenous infusion over 1 hour on Days 1, 2 and 3 of each 28-day cycle.

Conditions Studied

Advanced Solid Tumors

Interventions

  • DRUG G-202

Study Locations (3)

Maryland

  • Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins - Baltimore

Texas

  • University of Texas, Health Science Center,Cancer Therapy and Research Center - San Antonio

Wisconsin

  • University of Wisconsin Paul P Carbone Comprehensive Cancer Center - Madison

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2010-01
Est. Completion 2013-08
Phase Phase 1

Sponsor

GenSpera

5 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01056029

The ClinicalTrials.gov registry entry for NCT01056029 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 198-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (85% lower). The listed sponsor is GenSpera, which has 5 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Advanced Solid Tumors appearing as the primary indexed condition, and to 1 intervention - of which G-202 is the first listed.

NCT01056029 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Maryland, Texas, Wisconsin.

Frequently Asked Questions

What is clinical trial NCT01056029 about?

NCT01056029 is a clinical study titled "Dose-Escalation Phase 1 Study of G-202 (Mipsagargin) in Patients With Advanced Solid Tumors". This is an open-label, single-arm, dose-escalation Phase I study to determine the maximum tolerated dose (MTD) of G-202 (mipsagargin) when administered once daily for 3 consecutive days of a 28-day cycle in patients with advanced solid tumors. G-202 will be administered by intravenous infusion over ...

What is the current status of trial NCT01056029?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2010-01. Estimated completion is 2013-08.

What conditions does trial NCT01056029 study?

This clinical trial studies the following conditions: Advanced Solid Tumors.

What interventions are being tested in trial NCT01056029?

The interventions under investigation include: G-202 (DRUG).

Who is sponsoring clinical trial NCT01056029?

This trial is sponsored by GenSpera, which has 5 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01056029 being conducted?

This trial has 3 study locations across Maryland, Texas, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced Solid Tumors

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Advanced Solid Tumors

All registered trials for this condition

Maryland

All trials with a study site in Maryland

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.